The SELECT Trial: Semaglutide Cut Heart Risk 20%

GLP-1 Drugs and Heart Disease

20%

Reduction in major adverse cardiovascular events with semaglutide 2.4 mg vs. placebo in patients with obesity and established heart disease but no diabetes.

Lincoff et al., NEJM, 2023

Lincoff et al., NEJM, 2023

View as image

Before the SELECT trial, every GLP-1 receptor agonist cardiovascular outcomes trial enrolled patients with type 2 diabetes. SELECT changed that. It enrolled 17,604 patients who were overweight or obese with established cardiovascular disease but no diabetes, and randomized them to semaglutide 2.4 mg weekly or placebo.^[1] The result: a 20% reduction in heart attacks, strokes, and cardiovascular death. This was the first large-scale proof that a GLP-1 receptor agonist protects the heart independently of blood sugar control.

What was the SELECT trial?

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) was a randomized, double-blind, placebo-controlled, event-driven phase 3 trial conducted across 41 countries. Enrollment ran from October 2018 to March 2021.^[1]

The eligibility criteria defined a specific population: adults aged 45 or older, with a BMI of 27 kg/m2 or greater, with established atherosclerotic cardiovascular disease (prior heart attack, stroke, or peripheral artery disease), and without diabetes. Patients were randomized 1:1 to semaglutide 2.4 mg or placebo, titrated over 16 weeks to the target dose.

The primary endpoint was three-point MACE: a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The trial was event-driven, meaning it continued until a prespecified number of events had accumulated. Mean follow-up was 39.8 months.^[1]

What made SELECT unique was the deliberate exclusion of diabetes. Previous GLP-1 receptor agonist cardiovascular outcomes trials, including SUSTAIN-6 for semaglutide and LEADER for liraglutide, had enrolled exclusively diabetic patients.^[2][3] The question SELECT asked was whether the cardiovascular protection seen in those trials was actually about glucose control, or about something else entirely.

Primary results: 20% MACE reduction

A primary endpoint event occurred in 569 of 8,803 patients (6.5%) in the semaglutide group and 701 of 8,801 patients (8.0%) in the placebo group. The hazard ratio was 0.80 (95% CI 0.72-0.90, P less than 0.001).^[1]

All three components of the MACE composite contributed to the benefit:

• Cardiovascular death: reduced, though not individually statistically significant at the prespecified threshold
• Nonfatal myocardial infarction: reduced
• Nonfatal stroke: reduced

The hazard ratio for the heart failure composite endpoint (cardiovascular death or hospitalization/urgent visit for heart failure) was 0.82 (95% CI 0.71-0.96). All-cause death showed a 19% reduction with a hazard ratio of 0.81 (95% CI 0.71-0.93).^[1]

The all-cause mortality reduction is particularly noteworthy. Demonstrating a mortality benefit in a cardiovascular outcomes trial is unusually difficult. Many drugs that reduce heart attacks and strokes show no clear signal on overall survival. The fact that semaglutide produced a 19% reduction in death from any cause in a non-diabetic population made it one of the most consequential cardiovascular trial results in years.

How SELECT compares to earlier GLP-1 heart trials

SELECT did not arrive in a vacuum. Two earlier trials had already established GLP-1 receptor agonists as cardiovascular-protective drugs in patients with type 2 diabetes.

SUSTAIN-6 (2016) tested semaglutide at doses of 0.5 mg and 1.0 mg (lower than SELECT's 2.4 mg) in 3,297 patients with type 2 diabetes and high cardiovascular risk. The hazard ratio for three-point MACE was 0.74 (95% CI 0.58-0.95), a 26% relative reduction driven primarily by a decrease in nonfatal stroke.^[2]

LEADER (2016) tested liraglutide 1.8 mg daily in 9,340 patients with type 2 diabetes. The hazard ratio for MACE was 0.87 (95% CI 0.78-0.97), a 13% reduction, with a significant decrease in cardiovascular death.^[3]

A post hoc analysis across the SUSTAIN and PIONEER trial programs found that semaglutide reduced cardiovascular events consistently across the entire continuum of cardiovascular risk, not only in the highest-risk patients.^[5]

SELECT extended these findings in three important ways. First, it proved that cardiovascular protection occurs without diabetes, establishing that glucose lowering is not the primary mechanism. Second, it used the highest approved dose (2.4 mg), suggesting a dose-response relationship for cardiovascular benefit. Third, it demonstrated an all-cause mortality signal, which neither SUSTAIN-6 nor LEADER had clearly shown.

Heart failure subanalysis: even larger benefits

A prespecified analysis of SELECT focused on the 4,286 patients (24.3%) who had heart failure at enrollment. The results, published in The Lancet by Deanfield and colleagues, showed that semaglutide's benefits were amplified in this subgroup.^[4]

In patients with heart failure, MACE was reduced by 28% (HR 0.72, 95% CI 0.60-0.87). The heart failure composite endpoint (cardiovascular death or hospitalization for heart failure) was reduced by 21% (HR 0.79, 95% CI 0.64-0.98). Cardiovascular death was reduced by 24% (HR 0.76, 95% CI 0.59-0.97).^[4]

The benefits were consistent across heart failure subtypes. In heart failure with reduced ejection fraction (HFrEF), MACE hazard ratio was 0.65 (95% CI 0.49-0.87). In heart failure with preserved ejection fraction (HFpEF), it was 0.69 (95% CI 0.51-0.91).^[4]

This is important because HFpEF has historically been difficult to treat. Few drugs have demonstrated meaningful benefit in HFpEF trials. Semaglutide's consistent effect across both heart failure subtypes, combined with separate data from the STEP-HFpEF trial showing semaglutide improved symptoms and physical function in obese HFpEF patients, has positioned GLP-1 receptor agonists as a potential new treatment class for heart failure.^[7]

Beyond weight loss: how semaglutide may protect the heart

Patients on semaglutide in SELECT lost an average of 9.4% of their body weight, compared to 0.9% on placebo. Weight loss itself reduces cardiovascular risk. But multiple lines of evidence suggest that semaglutide's heart protection goes beyond what weight loss alone can explain.^[1]

Subanalyses of SELECT found that the cardiovascular benefit was present even after adjusting for the degree of weight loss. Patients who lost less weight still experienced meaningful MACE reduction. The cardiovascular benefit also emerged within months, faster than would be expected from weight loss-mediated improvements in blood pressure, lipids, or insulin resistance alone.

GLP-1 receptors are expressed throughout the cardiovascular system, including in cardiomyocytes, vascular endothelial cells, and smooth muscle cells. Preclinical research has identified several direct mechanisms by which GLP-1 receptor activation may protect the heart.^[6]

These include reduction of arterial inflammation and atherosclerotic plaque instability, improvement in endothelial function, reduced oxidative stress in vascular tissue, and suppression of pro-inflammatory cytokines including TNF-alpha, IL-6, and CRP.^[6][8]

Semaglutide also improves several traditional cardiovascular risk factors beyond weight: it lowers systolic blood pressure by 3-5 mmHg, reduces triglycerides, lowers CRP (a marker of systemic inflammation), and modestly improves the lipid profile.^[1] The likely explanation is that cardiovascular protection from semaglutide is multifactorial: some attributable to weight loss, some to anti-inflammatory effects, some to direct vascular biology, and some to risk factor modification.

Safety and discontinuation rates

SELECT's safety data requires honest accounting. While semaglutide reduced cardiovascular events and death, more patients discontinued the drug due to adverse events.

Adverse events leading to permanent discontinuation occurred in 16.6% of semaglutide patients versus 8.2% on placebo.^[1] The primary driver was gastrointestinal side effects: nausea, vomiting, and diarrhea. These are well-established class effects of GLP-1 receptor agonists and are generally worst during the dose-escalation period.

Serious adverse events, however, were less frequent with semaglutide than placebo. This distinction matters. More people stopped taking the drug due to discomfort, but among those who took it, serious medical complications were rarer.

The discontinuation rate raises a practical question about real-world effectiveness. A 20% MACE reduction means little if a substantial fraction of patients cannot tolerate the drug. The clinical challenge is identifying patients who will tolerate the full 2.4 mg dose and maintain it long enough to realize the cardiovascular benefit. Slower dose titration and management of GI side effects are active areas of clinical research.

Trial limitations worth noting

SELECT was a rigorously designed trial, but several limitations affect how broadly its results can be applied.

The trial population was specific: adults over 45 with established atherosclerotic cardiovascular disease and BMI 27 or higher but no diabetes. Results may not directly apply to younger patients, those without established heart disease, or those with BMI below 27. Whether semaglutide provides primary prevention cardiovascular benefit (in people who have not yet had a heart attack or stroke) is unknown.

The 16.6% discontinuation rate means the intention-to-treat analysis likely underestimates the benefit in patients who can tolerate the drug, while simultaneously raising questions about real-world adherence. SELECT was also sponsored by Novo Nordisk, the manufacturer of semaglutide, which conducted the trial and funded the analysis.^[1]

The trial did not compare semaglutide to other cardiovascular interventions, so its relative benefit versus, for example, high-intensity statin therapy or SGLT2 inhibitors in this population cannot be determined from these data alone.

What SELECT means for GLP-1 drugs and cardiovascular medicine

SELECT repositioned semaglutide from a diabetes and weight loss drug to a cardiovascular drug. The trial's implications extend in several directions.

For clinical practice, SELECT supports prescribing semaglutide 2.4 mg specifically for cardiovascular risk reduction in obese patients with established heart disease, regardless of diabetes status. This expands the eligible population substantially. The Deanfield heart failure subanalysis further suggests benefit in patients with heart failure of either subtype.^[4]

For understanding GLP-1 biology, SELECT confirms that the cardiovascular effects of GLP-1 receptor agonism are not primarily mediated by glucose control. This has accelerated research into the direct cardiovascular biology of GLP-1 receptors, including their roles in inflammation, endothelial function, and cardiac metabolism.^[6]

For the pharmaceutical landscape, SELECT data contributed to semaglutide's indication expansion for cardiovascular risk reduction and strengthened the commercial case for the entire GLP-1 receptor agonist class. Semaglutide's weight loss data in non-diabetic patients was already driving enormous demand; adding a cardiovascular mortality benefit transforms the risk-benefit calculation.

Open questions remain. Whether lower doses of semaglutide (0.5 mg or 1.0 mg) provide proportional cardiovascular protection is unknown. Whether the cardiovascular benefit persists after drug discontinuation, or reverses when patients regain weight, has not been studied in a dedicated trial. And whether newer multi-agonists like tirzepatide will match or exceed SELECT's cardiovascular results is being tested in ongoing trials like SURPASS-CVOT, while tirzepatide's SUMMIT trial has already shown heart failure benefits in obese patients.

The Bottom Line

The SELECT trial demonstrated that semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% and all-cause death by 19% in 17,604 patients with obesity and established cardiovascular disease but without diabetes. Heart failure subanalyses showed even larger benefits (28% MACE reduction), consistent across HFpEF and HFrEF. The cardiovascular protection appears to extend beyond weight loss, likely involving direct anti-inflammatory and vascular effects of GLP-1 receptor activation. SELECT established GLP-1 receptor agonists as cardiovascular drugs, not merely metabolic ones.

Frequently Asked Questions

What was the main result of the SELECT trial?

The SELECT trial showed that semaglutide 2.4 mg weekly reduced the combined risk of cardiovascular death, heart attack, and stroke by 20% compared to placebo in patients with obesity and established heart disease but no diabetes. The hazard ratio was 0.80 (95% CI 0.72-0.90, P less than 0.001).^[1] All-cause death was also reduced by 19%.

Did SELECT trial patients have diabetes?

No. SELECT specifically excluded patients with diabetes. All 17,604 participants had obesity or overweight (BMI 27 or higher) and established cardiovascular disease, but no diabetes diagnosis. This was the first major cardiovascular outcomes trial for a GLP-1 agonist in a non-diabetic population, proving that the heart benefits are not dependent on blood sugar control.^[1]

How does SELECT compare to the SUSTAIN-6 trial?

SUSTAIN-6 tested lower-dose semaglutide (0.5 mg and 1.0 mg) in 3,297 patients with type 2 diabetes and found a 26% MACE reduction (HR 0.74). SELECT tested higher-dose semaglutide (2.4 mg) in 17,604 non-diabetic patients and found a 20% MACE reduction (HR 0.80). SELECT was five times larger, excluded diabetes, and demonstrated an all-cause mortality benefit that SUSTAIN-6 did not clearly show.^[2]

Does semaglutide help with heart failure?

A prespecified analysis of SELECT found that semaglutide reduced MACE by 28% (HR 0.72) in patients who had heart failure at enrollment. Benefits were consistent across both heart failure with preserved ejection fraction (HFpEF, HR 0.69) and heart failure with reduced ejection fraction (HFrEF, HR 0.65). Cardiovascular death was reduced by 24% in the heart failure subgroup.^[4]

Is the cardiovascular benefit of semaglutide just from weight loss?

Probably not entirely. Semaglutide patients in SELECT lost 9.4% of body weight on average, and weight loss does reduce cardiovascular risk. But subanalyses found that MACE reduction persisted even after adjusting for degree of weight loss, and benefits emerged faster than weight loss alone would predict. Direct anti-inflammatory and vascular effects of GLP-1 receptor activation likely contribute independently.^[6]

What were the side effects in the SELECT trial?

The most common side effects were gastrointestinal: nausea, vomiting, and diarrhea, consistent with the known GLP-1 receptor agonist class profile. 16.6% of semaglutide patients permanently discontinued treatment due to adverse events, compared to 8.2% on placebo. However, serious adverse events were actually less common with semaglutide than placebo.^[1]